Vascular Endothelial Growth Factor Antibodies Market – Global Segments and Forecasts up to 2023: Transparency Market Research


Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen that stimulates the proliferation, migration and survival of endothelial cells. The human VEGF family consists of five ligands, namely, VEGF (or VEGF-A), VEGF-B VEGF-D VEGF-D and placental growth factor. Vascular endothelial growth factor is involved in several pathophysiological processes and is therefore a popular approach for developing therapies to treat related diseases such as cancers and macular degeneration. The market for VEGF antibodies is gaining traction since it offers several advantages over pharmaceuticals such as lower frequency of administration in product with extended half-life. It is noteworthy that the VEGF antibodies targeted towards treatment of cancer contributes to more than half of the global VEGF antibodies market revenue.

Bevacizumab (Avastin) from Genentech-Roche is the first FDA approved recombinant monoclonal antibody developed to target VEGF for treating metastatic colorectal cancer in combination with the chemotherapy drugs such as 5-fluorouracil (5-FU). Some of the major cancer types which can be treated using VEGF antibody therapy include advanced colorectal cancer, advanced non small cell lung cancer, metastatic breast cancer, and advanced renal cell cancer.  Multiple clinical trials are ongoing to assess safety and efficacy of VEGF antibodies in variety of other malignancies and other diseases as well. It has been well acknowledged that the VEGF plays an important role in development of diabetic retinopathy and wet form of age-related macular degeneration (AMD).

The anti-VEGF therapy may be ineffective in certain cases due to the complex VEGF pathway. For instance, Avastin becomes futile by tumor escape and relapse possibly due to up-regulation of alternate pro-angiogenic factors such as VEGF-C or VEFG-D. Therefore, research and development focusing on other ligands in the VEGF pathway, VEGF receptors and their tyrosine kinase signaling have been developed in the recent years. Apart from Avastin, the other agents which target the VEGF-mediated signaling pathway critical to angiogenesis include Cometriq (cabozantinib, Exelixis, Inc.), Cyramza (ramucirumab, Eli Lilly and Company), Eylea (aflibercept, Bayer Pharma AG), Jetrea, Lucentis (ranibizumab, Genentech), Macugen (pegaptanib, Valeant Pharmaceuticals), and Zaltrap (ziv-aflibercept, Regeneron Pharmaceuticals, Inc.). In June 2014, Ceres Oncology Pty Ltd (a subsidiary of Circardian Technologies Limited) announced clinical and safety data for its VEFG-C antibody, VGX-100, in the patients with advanced solid tumors.

The success of first generation VEGF antibodies has laid foundation for the market development and patent expiry of these products are expected to provide opportunity for investing in biosimilars manufacturing as well as developing next generation products. In a very recent development in the market, OncoMed Pharmaceuticals received was granted the U.S. patent for its anti-DLL4/anti-VEGF bispecific antibody for using in cancer treatment. The activity of anti-DLL4 is expected to complement the action of anti-VEGF thereby forming a highly potent combination product for treating cancer. The global VEGF antibodies market is therefore expected to witness launch of several promising emerging therapies in the near future which shall possess novel mode of action and convenience of usage. Moreover, the increasing research in the personalized medicine and diagnostics will lead to targeting VEGF antibodies to only those patients who are likely to derive most benefit from targeted treatment. The optimization of therapy will increase efficacy and avoid certain toxicities resulting into more uptake of the products in the near future.

Some of the key companies operating in the VEGF antibodies market include and Genentech (a Roche company), Abcam plc, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Valeant Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Ceres Oncology Pty Ltd (a subsidiary of Circardian Technologies Limited), Santen Pharmaceutical Co. Ltd., and BioVision, Inc.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America
Asia Pacific
Middle East and Africa
Latin America

This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments

Request For Brochure:-

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +15186181030


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s